# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
European Commission Approval Followed By Anticipated EU And UK Launches In Q1 2025; Strategic Partnership With Cencora To Suppo...
HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $30 pric...
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(1.55) per share which missed the analyst consensus estimate o...
-SEC Filing
Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades.